Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
CROI 2015: European PrEP Studies Find High and Equivalent HIV Protection
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 24 February 2015 00:00
- Written by HIVandHepatitis.com
The UK PROUD study of once-daily Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis (PrEP), and the French Ipergay study of "on-demand" PrEP taken before and after sex, both saw an 86% reduction in new HIV infections, researchers reported at the at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle.
PrEP Stops 86% of HIV Infections in PROUD Study
On-Demand PrEP Prevents 86% of HIV Infections in Ipergay
PrEP Provides 86% Protection in 2 Studies [VIDEO]
Study of Truvada PrEP and Tenofovir Vaginal Gel Misses Mark Due to Low Adherence
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 11 February 2015 00:00
- Written by Gus Cairns
The final published report in the New England Journal of Medicine from the VOICE trial of HIV prevention for women in 3 African countries mainly reinforces what conference presentations have already shown: this ambitious trial failed to demonstrate the effectiveness of either oral pre-exposure prophylaxis (PrEP) or of a tenofovir-containing vaginal microbicide gel, and the reason for this was that only 25%-30% of women actually used the study product, despite 88% claiming they did so. The gel, however, may have stopped 2 out of 3 infections among women who used it.
Long-acting Injectable Cabotegravir Shows Promise as PrEP in Monkey Studies
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 21 January 2015 00:00
- Written by Liz Highleyman
A long-acting injected formulation of the HIV integrase inhibitor cabotegravir (GSK1265744) prevented infection of most macaque monkeys vaginally exposed to an HIV-like hybrid virus at drug concentrations achievable with monthly dosing, according to a pair of studies published in the January 14 issue of Science Translational Medicine.
Truvada for PrEP Not Linked to Kidney Impairment, Resistance Is Rare
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Thursday, 29 January 2015 00:00
- Written by Liz Highleyman
Truvada (tenofovir/emtricitabine) used for pre-exposure prophylaxis (PrEP) was not associated with clinically relevant declines in kidney function through 36 months in a large clinical trial, researchers recently reported. A related study found that drug resistance is rare among PrEP users, but it can occur in people who have acute HIV infection when they start Truvada and those who become infected despite PrEP.
HIV PrEP Forum Discusses Research, Personal Experiences, and Access
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Friday, 16 January 2015 00:00
- Written by Liz Highleyman
Nearly 100 people gathered on January 11 in San Francisco's Castro neighborhood to learn about the latest research on HIV pre-exposure prophylaxis -- better known as PrEP -- and how they can get help paying for it.
Web Design and Development by